Navigation Links
Local therapy followed by treatment with EGFR TKI is well tolerated

DENVER Local therapy is not commonly utilized in metastatic lung cancer. Researchers at Memorial Sloan-Kettering Cancer Center investigated the efficacy of local therapy with continued EGFR TKI therapy specifically in patients with acquired resistance to EGFR TKIs. A recent study published in the March 2013 issue of the International Association for the Study of Lung Cancer's (IASLC) Journal of Thoracic Oncology, found that EGFR- mutant lung cancers with acquired resistance to EGFR TKI therapy are amenable to local therapy to treat oligometastatic disease when used in conjunction with continued EGFR inhibition.

Eighteen patients were identified who received elective local therapy (surgical resection, radiofrequency ablation or radiation). Local therapy was well-tolerated, with 85 percent of the patients restarting TKI therapy within one month of local therapy. Local therapy with surgery, radiation, or radiofrequency ablation in selected patients is associated with a median overall survival of 41 months, a median time to progression of 10 months, and a median time to next systemic therapy of 22 months.

Researchers report that, "these remarkable outcomes in patients with EGFR mutant lung cancer are likely a result of multiple factors including the unique clinical course of this disease, patient selection, continued benefits of the TKI even after progression, and potential benefits of local therapy."

They also say, "While the patients reported here had long median overall survivals and delayted time to disease progression, there was a wide range of outcomes. Outcomes appeared to be best when the site of local therapy was the only known site of disease." Their experience suggests, "local therapy should be considered for patients with oligometastatic lung cancer with acquired resistance to EGFR TKI."


Contact: Kristal Griffith
International Association for the Study of Lung Cancer

Page: 1

Related biology news :

1. Chinese scientists discover evidence of giant pandas population history and local adaptation
2. Maple syrup, moose, and the local impacts of climate change
3. Greater effort needed to move local, fresh foods beyond privileged consumers
4. Global economic pressures trickle down to local landscape change, altering disease risk
5. In Fiji, marine protection gets local boost
6. Long-distance distress signal from periphery of injured nerve cells begins with locally made protein
7. First paternity study of southern right whales finds local fathers most successful
8. Managing biodiversity data from local government
9. New therapy for heart failure may enhance bodys stem cell response at cardiovascular injury site
10. Cell therapy a little more concrete thanks to VIB research
11. Preclinical study shows potential of new technologies to detect response to cancer therapy earlier
Post Your Comments:
(Date:6/2/2016)... -- The Department of Transport Management (DOTM) of ... US Dollar project, for the , Supply and ... and IT Infrastructure , to Decatur ... of Identity Management Solutions. Numerous renowned international vendors participated in ... was selected for the most compliant and innovative solution. ...
(Date:6/2/2016)... June 2, 2016 Perimeter Surveillance ... Unmanned Systems, Physical Infrastructure, Support & Other Service  ... visiongain offers comprehensive analysis of the global ... will generate revenues of $17.98 billion in 2016. ... Inc, a leader in software and hardware technologies for ...
(Date:5/24/2016)... , May 24, 2016 Ampronix facilitates superior patient care by providing ...  3D medical LCD display is the latest premium product recently added to the range ... ... ... Sony 3d Imaging- LCD Medical Display- Ampronix News ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... ... 23, 2016 , ... Mosio, a leader in clinical research ... Recruitment and Retention Tips.” Partnering with experienced clinical research professionals, Mosio revisits the ... tools, and strategies for clinical researchers. , “The landscape of how patients receive ...
(Date:6/23/2016)... 2016 /PRNewswire/ - FACIT has announced the creation ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" or "the ... a portfolio of first-in-class WDR5 inhibitors for the ... WDR5 represent an exciting class of therapies, possessing ... for cancer patients. Substantial advances have been achieved ...
(Date:6/23/2016)... ... June 23, 2016 , ... ... (Yeast and Mold) microbial test has received AOAC Research Institute approval 061601. , ... tests introduced last year,” stated Bob Salter, Vice President of Regulatory and Industrial ...
(Date:6/23/2016)... 23, 2016   EpiBiome , a precision microbiome ... in debt financing from Silicon Valley Bank (SVB). The ... to advance its drug development efforts, as well as ... "SVB has been an incredible strategic partner to ... traditional bank would provide," said Dr. Aeron Tynes ...
Breaking Biology Technology: